Superior post-scan disease upstaging in patients with recurrent prostate cancer was observed with 18F-rhPSMA-7.3 compared with conventional baseline imaging.
Patients with endometrial cancer who have low volumetric skeletal muscle measurements had lower 3-year overall and progression-free survival rates.
Patients with untreated unresectable or metastatic urothelial carcinoma and PD-L1 expression of 1% or more who received treatment with nivolumab and ipilimumab in the first-line setting did not experience an improved overall survival vs those getting standard-of-care chemotherapy, according to a final analysis of a phase 3 trial.
Lisa Sprod, PhD, MPH, provides perspective on a cancer-related fatigue assessment tools.
This review article written by Danielle Gentile, PhD, et al, reviews the management of cancer-related fatigue in integrative oncology.
David M. O’Malley, MD, spoke about where the future of treatment is heading for patients with endometrial cancer.
A panel of experts in stem cell transplant and cellular immunotherapy builds a lively discussion on current and emerging treatment options for the management of acute and chronic graft versus host disease.
The phase 3 ACHIEVE trial analyzed Asian patients with stage III colon cancer to determine how a 3-month treatment duration with capecitabine and oxaliplatin compared with 6 months.
Alina Markova, MD, discusses the rationale for assessing topical ruxolitinib INCB018424 phosphate 1.5% cream in patients with non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.
Leukemia survivors who were adolescents or young adults had worse long-term survival outcomes vs the general population.